1. Home
  2. MI vs VIVS Comparison

MI vs VIVS Comparison

Compare MI & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NFT Limited

MI

NFT Limited

N/A

Current Price

$10.23

Market Cap

3.4M

ML Signal

N/A

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

HOLD

Current Price

$1.05

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MI
VIVS
Founded
2009
2007
Country
Hong Kong
United States
Employees
N/A
9
Industry
Catalog/Specialty Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
3.9M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
MI
VIVS
Price
$10.23
$1.05
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.4K
74.1K
Earning Date
05-07-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$42.38
Revenue Next Year
N/A
$15.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.95
52 Week High
$19.84
$5.30

Technical Indicators

Market Signals
Indicator
MI
VIVS
Relative Strength Index (RSI) 39.88 33.65
Support Level $3.51 N/A
Resistance Level $19.15 $1.38
Average True Range (ATR) 1.17 0.08
MACD -0.94 -0.00
Stochastic Oscillator 1.18 36.51

Price Performance

Historical Comparison
MI
VIVS

About MI NFT Limited

NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: